Laurene Wang
Principal investigator, leads AIMMAX THERAPEUTICS INC.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$4.7MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $4.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 21, 2025 | NIH | SBIR Phase II Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $1.0M | AIMMAX THERAPEUTICS INC |
| Aug 8, 2024 | NIH | SBIR Phase II Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $1000K | AIMMAX THERAPEUTICS INC |
| Mar 25, 2024 | NIH | SBIR Phase II A Single Dose Therapy to Treat Drug Resistant Gonorrhea | $306K | AIMMAX THERAPEUTICS INC |
| Aug 1, 2023 | NIH | SBIR Phase II Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $1000K | AIMMAX THERAPEUTICS INC |
| Jun 21, 2023 | NIH | SBIR Phase II Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $1000K | AIMMAX THERAPEUTICS INC |
| Aug 8, 2022 | NIH | SBIR Phase II Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | $307K | AIMMAX THERAPEUTICS INC |
1 patents as inventor
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#302
Awards as PI#315
Patents#273
Companies
- AIMMAX THERAPEUTICS INCLeads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.